Abstract: Bronchial asthma and other bronchospastic and allergic diseases are treated by administering an effective amount of a substituted xanthine compound having the formula: ##STR1## wherein: R.sub.1 = C.sub.1 -C.sub.3 alkyl,R.sub.3 = c.sub.1 -c.sub.7 alkyl, C.sub.3 -C.sub.7 alkenyl, C.sub.3 -C.sub.7 alkynyl, C.sub.3 -C.sub.7 cycloalkyl or C.sub.4 -C.sub.7 cycloalkylalkyl,R.sub.8 = h, c.sub.1 -c.sub.4 alkyl, C.sub.3 -C.sub.4 alkenyl, C.sub.3 -C.sub.4 alkynyl or C.sub.3 -C.sub.4 cycloalkyl,R = c.sub.1 -c.sub.4 alkyl, 2-halo C.sub.2 -C.sub.3 alkyl, or phenylNovel and preferred bronchodilator and antiallergy compounds are disclosed having the formula ##STR2## wherein: R.sub.1 = C.sub.1 -C.sub.2 alkylR.sub.3 = ch.sub.2 --(c.sub.3 -c.sub.4 alkyl),--CH.sub.2 --(C.sub.3 -C.sub.4 alkenyl), or --CH.sub.2 --(C.sub.3 -C.sub.4 cycloalkyl)R.sub.8 = h, c.sub.1 -c.sub.2 alkyl,R = c.sub.1 -c.sub.4 alkyl, 2-halo C.sub.2 -C.sub.

Abstract: An ophthalmic solution is disclosed comprising an aqueous solution of polyvinyl alcohol, hydroxyethyl cellulose, polyvinylpyrrolidone, and, optionally, hydroxypropyl methylcellulose. The ophthalmic solution is used in treating dry eye syndrome due to insufficient tear production in humans and mammals, and as an ocular lubricant for inflamed eyes.

Abstract: A fuel assembly for a light-water or heavy-water reactor or for a fast reactor comprises a bundle of clad fuel pins disposed on a uniform lattice and maintained in parallel relation by means of separate spacer grids fitted with resilient members for applying the grids against the fuel pins. A rigid support structure is formed by two parallel end-plates braced by tie-rods having the same diameter as the fuel pins and disposed at uniform intervals at the lattice nodes. The fuel-pin bundle is associated with a single support grid rigidly fixed at the mid-point of the tie-rods, the other grids being uniformly spaced in the vertical direction on each side so that elongation of the fuel pins takes place upwards and downwards from the support grid.

Abstract: Antimicrobial compounds are disclosed having the formula:Z--B--Y--B --Z .sup.. nHAwherein B is carbamylguanidino, or thiocarbamylguanidino, Y is a bivalent organic radical selected from the group consisting of C.sub.2 -C.sub.12 alkylene, C.sub.5 -C.sub.12 cycloalkylene, C.sub.5 -C.sub.12 cycloalkylenebis(loweralkyl), C.sub.6 -C.sub.12 arylene and loweralkylarylene, C.sub.7 -C.sub.12 aryleneloweralkyl, and C.sub.8 -C.sub.12 arylenebis(loweralkyl) and Z is selected from the group consisting of C.sub.1 -C.sub.12 alkyl; C.sub.4 -C.sub.12 dialkylaminoalkyl; C.sub.3 -C.sub.12 alkenyl; C.sub.3 -C.sub.12 alkynyl; C.sub.3 -C.sub.12 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl; C.sub.1 -C.sub.10 alkoxy C.sub.10 -C.sub.2 alkyl having a total carbon content of C.sub.3 -C.sub.14 ; C.sub.1 -C.sub.10 alkylthio C.sub.10 -C.sub.2 alkyl having a total carbon content of C.sub.3 -C.sub.14 ; phenoxy C.sub.2 -C.sub.6 alkyl; phenylthio C.sub.2 -C.sub.6 alkyl; C.sub.6 -C.sub.14 aryl; C.sub.7 -C.sub.

Abstract: Antimicrobial compounds are disclosed having the formula:Z--B--Y--B--Z .rHAwherein B is carbamylguanidino or thiocarbamylguanidino, Y is a nitrogen-containing alkylene group having the structural formula: ##STR1## WHEREIN: N = 2-4m = 2-4p = 1,2q = 2-4x = 0-3y = 0-2x = 0 when y .noteq. 0 and y = 0 when x .noteq. 0,And R is hydrogen or a C.sub.1 -C.sub.8 hydrocarbon radical selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, and aralkyl radicals, R' and R" are each hydrogen or C.sub.1 -C.sub.4 alkyl and may be the same or different and Z is selected from the group consisting of C.sub.1 -C.sub.12 alkyl, di(C.sub.1 -C.sub.10 alkylamino)-C.sub.10 -C.sub.2 having a total carbon content of C.sub.4 -C.sub.12 ; C.sub.3 -C.sub.12 alkenyl; C.sub.3 -C.sub.12 alkynyl; C.sub.3 -C.sub.12 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl; C.sub.6 -C.sub.12 cycloalkenyl, C.sub.7 -C.sub.14 cycloalkenylalkyl, C.sub.7 -C.sub.12 polycycloalkyl, C.sub.8 -C.sub.14 polycycloalkylalkyl, C.sub.7 -C.sub.

Abstract: A metal layer deposited on a wafer opposite to the photocathode is brought to a potential which is at least equal to that of the photocathode. The wafer layer and screen layer form conductors for a biplanar wave-propagation line element having a characteristic impedance equal to that of an external propagation line. The shutter tube is provided with matched means for connecting the line element to the external line, a voltage signal being applied to the line element so that the screen layer is brought progressively to a higher potential than that of the wafer layer.

Abstract: Pharmaceutical vehicles for delivery of pharmacologically active chemical materials to mucous membranes, as well as pharmaceutically active compositions containing such vehicles, are provided. The pharmaceutical vehicles are clear, water-miscible, physiologically-acceptable, liquid compositions which gel to a thickened, non-flowing and adhering consistency at human body temperature. They are liquid at ambient room temperature and have a gel transition temperature in the range of from about 25.degree. to about 40.degree. C. Aqueous solutions of certain polyoxyethylene-polyoxypropylene condensates are suitable vehicles. Also provided are pharmaceutical compositions containing added pharmacologically active chemical material, i.e., a drug or medicament. A method of delivering the drug or medicament to a mucous membrane is also provided.

Abstract: A method for lowering intraocular pressure in mammals by administering thereto an effective amount of antazoline, i.e., 2-(N-benzylanilinomethyl)-2-imidazoline or its pharmacologically acceptable acid addition salts, preferably antazoline phosphate.

Abstract: Prolonged bronchodilation and prolonged inhibition of allergic mediator release in mammals are produced by administering an effective amount of a substituted xanthine compound having the formula: ##STR1## wherein: R.sub.1 = methylR.sub.3 = c.sub.4 -c.sub.7 alkyl, C.sub.4 -C.sub.7 cycloalkylalkyl C.sub.4 -C.sub.7 alkenyl, C.sub.4 -C.sub.7 alkynyl, or C.sub.4 -C.sub.7 cycloalkylR.sub.8 = c.sub.1 -c.sub.2 alkylThese compounds are useful in the treatment of bronchial asthma and other bronchospastic and allergic diseases. The compounds are also novel.The bronchodilator and antiallergy agents may be administered in the form of tablets, capsules, aerosols, solutions, suspensions or suppositories.

Abstract: A method of manufacturing a contact lens by machining a lens blank in a suitable machinable condition. The concave lens surface is machined first and the circumferential edge surface is then machined with the blank mounted in the same position. The partly formed blank is repositioned and the convex lens surface machined.

Abstract: Antimicrobial compounds are disclosed having the formula:Z--B--Y--B'--Z .nHAwherein B is carbamylguaidino, or thiocarbamylguanidino and B' is B or biguanidino provided that B' is biguanidino only when B is carbamylguanidino bonded to Y through the guanidino portion of the group, Y is a bivalent organic radical selected from the group consisting of C.sub.2 -C.sub.12 alkylene, C.sub.5 -C.sub.12 cycloalkylene, C.sub.5 -C.sub.12 cycloalkylenebis(loweralkyl), C.sub.6 -C.sub.12 arylene and loweralkylarylene, C.sub.7 -C.sub.12 aryleneloweralkyl, and C.sub.8 -C.sub.12 arylenebis(loweralkyl) and Z is selected from the group consisting of C.sub.1 -C.sub.12 alkyl; C.sub.4 -C.sub.12 dialkylaminoalkyl; C.sub.3 -C.sub.12 alkenyl; C.sub.3 -C.sub.12 alkynyl; C.sub.3 -C.sub.12 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl; C.sub.1 -C.sub.10 alkoxy C.sub.10 -C.sub.2 alkyl having a total carbon content of C.sub.3 -C.sub.14 ; C.sub.1 -C.sub.10 alkylthio C.sub.10 -C.sub.2 alkyl having a total carbon content of C.sub.3 -C.sub.

Abstract: A reusable, longitudinally adjustable, readily removable form support member for supporting a concrete construction form in an array of structural members in a building construction. In one embodiment the form support member comprises a spanning member having laterally translatably support pin members secured in recesses in opposed ends of the spanning member for engaging openings in adjacent structural members. The support pins may be movable in a horizontal plane so as to permit their alignment with the structural openings where necessary. The support pin members include block means attached to the rear portions of the support pins, the block means cooperating with respective activating means to move the spanning member in a vertical plane so that an inside surface of the respective end parts of the spanning member contacts a surface of the block means and effect a friction bond which prevents longitudinal movement of the respective parts.

Abstract: A process for encapsulation is provided. Generally, the materials involved are those which tend to lose at least part of their original properties upon exposure to auto-oxidative, thermal, or humid conditions. The process comprises constituting the material to be encapsulated in or as a viscid medium and dispersing the medium as particulates into an atmosphere containing an agitated quantity of a powdered, sorbent, film-forming agent. The dispersed particulates must have a tacky surface. The powdered agent adheres to this tacky surface and absorbs sufficient liquid to gel the coated particulates and to form a continuous, substantially non-crackable and dry encapsulating film around each of the particulates.

Abstract: A hydrophilic terpolymer suitable for manufacture into shaped articles, said terpolymer being substantially the polymerization product of hydroxyalkyl acrylate or methacrylate, a vinyl comonomer having a high affinity for water, e.g. N-vinyl pyrrolidone, and a polymerizable, unsaturated carboxylic acid, e.g. methacrylic or acrylic acid. The terpolymer is particularly adaptable for use as a contact lens by bringing it in contact with a buffered aqueous alkaline solution thereby affording a hydrogel having a water content between about 55-85% by weight of the total.A preferred embodiment of the invention is the polymerization product of a reaction mixture comprising 30-50% by weight of vinyl pyrrolidone, up to about 3% of a crosslinking agent such as ethylene glycol di-methacrylate, methacrylic acid amounting to about 0.25--3.5% by weight, and 2-hydroxyethyl methacrylate which constitutes the balance.